Biogen Idec Hemophilia Therapeutic Overview
- Year Founded
-
1997
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$124M
Biogen Idec Hemophilia Therapeutic General Information
Description
Developer of biopharmaceuticals for the treatment of patients with chronic hematologic disorders. The company involves in developing recombinant long-acting Fc fusion molecules to provide prolonged protection from bleeding.
Contact Information
Website
www.biogenidechemophilia.comCorporate Office
- 133 Boston Post Road
- Weston, MA 02493
- United States
Corporate Office
- 133 Boston Post Road
- Weston, MA 02493
- United States
Biogen Idec Hemophilia Therapeutic Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Merger/Acquisition | 01-Jan-2007 | $124M | Completed | Generating Revenue | ||
| 5. Later Stage VC (Series C) | 18-Jan-2006 | Completed | Generating Revenue | |||
| 4. Later Stage VC | 21-Sep-2005 | Completed | Generating Revenue | |||
| 3. Debt - General | 14-May-2004 | Completed | Clinical Trials - Phase 3 | |||
| 2. Early Stage VC (Series B) | 05-Apr-2002 | $35.8M | $50M | Completed | Startup | |
| 1. Early Stage VC (Series A) | 01-Jan-2000 | $14.2M | $14.2M | Completed | Startup |
Biogen Idec Hemophilia Therapeutic Former Investors (17)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Acquirer Systems | Corporation | Minority | ||
| Alta Partners | Venture Capital | Minority | ||
| BancBoston Ventures | Venture Capital | Minority | ||
| Bank of America | Investment Bank | Minority | ||
| Bay City Capital | Venture Capital | Minority |
Biogen Idec Hemophilia Therapeutic FAQs
-
When was Biogen Idec Hemophilia Therapeutic founded?
Biogen Idec Hemophilia Therapeutic was founded in 1997.
-
Where is Biogen Idec Hemophilia Therapeutic headquartered?
Biogen Idec Hemophilia Therapeutic is headquartered in Weston, MA.
-
What industry is Biogen Idec Hemophilia Therapeutic in?
Biogen Idec Hemophilia Therapeutic’s primary industry is Drug Discovery.
-
Is Biogen Idec Hemophilia Therapeutic a private or public company?
Biogen Idec Hemophilia Therapeutic is a Private company.
-
What is the current valuation of Biogen Idec Hemophilia Therapeutic?
The current valuation of Biogen Idec Hemophilia Therapeutic is .
-
What is Biogen Idec Hemophilia Therapeutic’s current revenue?
The current revenue for Biogen Idec Hemophilia Therapeutic is .
-
How much funding has Biogen Idec Hemophilia Therapeutic raised over time?
Biogen Idec Hemophilia Therapeutic has raised $72.3M.
-
Who are Biogen Idec Hemophilia Therapeutic’s investors?
Acquirer Systems, Alta Partners, BancBoston Ventures, Bank of America, and Bay City Capital are 5 of 17 investors who have invested in Biogen Idec Hemophilia Therapeutic.
-
When was Biogen Idec Hemophilia Therapeutic acquired?
Biogen Idec Hemophilia Therapeutic was acquired on 01-Jan-2007.
-
Who acquired Biogen Idec Hemophilia Therapeutic?
Biogen Idec Hemophilia Therapeutic was acquired by Biogen.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process